Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast Cancer.

Understanding interplay of breast cancer and microenvironment is critical. Here, we identified two transcriptomic subtypes and five immune infiltration patterns from RNA-seq and multiplex immunohistochemistry from 21 ER+/HER2- invasive lobular breast cancers. The proliferative subtype associated with increased immune infiltration especially by immunosuppressive regulatory T-cells and macrophages. We also defined a TAM-Low signature, which associated with lower infiltration of proliferative, pro-inflammatory TAM, and improved outcome in patients with ER+ tumors.

Déclaration de conflit d'intérêts

DAAV: cofounder and stock holder – Novasenta, Potenza, Tizona, Trishula; stock holder – Werewolf; patents licensed and royalties - BMS, Novasenta; scientific advisory board member - Werewolf, F-Star, Apeximmune, T7/Imreg Bio; consultant - BMS, Regeneron, Ono Pharma, Avidity Partners, Peptone; funding - BMS, Novasenta. Other authors declare no competing interests.